nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.112	0.355	CbGbCtD
Nilotinib—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.0594	0.189	CbGbCtD
Nilotinib—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0415	0.132	CbGbCtD
Nilotinib—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0402	0.128	CbGbCtD
Nilotinib—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.0379	0.12	CbGbCtD
Nilotinib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0241	0.0766	CbGbCtD
Nilotinib—MAPK8—endothelium—focal segmental glomerulosclerosis	0.0121	0.097	CbGeAlD
Nilotinib—TIE1—endothelium—focal segmental glomerulosclerosis	0.0105	0.0841	CbGeAlD
Nilotinib—EPHB4—endothelium—focal segmental glomerulosclerosis	0.00731	0.0584	CbGeAlD
Nilotinib—TEK—endothelium—focal segmental glomerulosclerosis	0.007	0.0559	CbGeAlD
Nilotinib—Hyperkeratosis—Cyclosporine—focal segmental glomerulosclerosis	0.00622	0.0297	CcSEcCtD
Nilotinib—Papilloedema—Cyclosporine—focal segmental glomerulosclerosis	0.00559	0.0267	CcSEcCtD
Nilotinib—Eye swelling—Cyclosporine—focal segmental glomerulosclerosis	0.00545	0.026	CcSEcCtD
Nilotinib—CDC42BPB—cortex of kidney—focal segmental glomerulosclerosis	0.00526	0.042	CbGeAlD
Nilotinib—KIT—endothelium—focal segmental glomerulosclerosis	0.00507	0.0405	CbGeAlD
Nilotinib—MAPK8—kidney—focal segmental glomerulosclerosis	0.00489	0.039	CbGeAlD
Nilotinib—MAPK8—cortex of kidney—focal segmental glomerulosclerosis	0.00476	0.038	CbGeAlD
Nilotinib—Swelling face—Cyclosporine—focal segmental glomerulosclerosis	0.00373	0.0178	CcSEcCtD
Nilotinib—CA7—kidney—focal segmental glomerulosclerosis	0.00362	0.0289	CbGeAlD
Nilotinib—EPHB4—nephron tubule—focal segmental glomerulosclerosis	0.00335	0.0267	CbGeAlD
Nilotinib—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.00329	0.0157	CcSEcCtD
Nilotinib—EPHA2—nephron tubule—focal segmental glomerulosclerosis	0.00328	0.0262	CbGeAlD
Nilotinib—Micturition urgency—Cyclosporine—focal segmental glomerulosclerosis	0.00313	0.0149	CcSEcCtD
Nilotinib—MAPK14—kidney—focal segmental glomerulosclerosis	0.0031	0.0248	CbGeAlD
Nilotinib—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00309	0.0148	CcSEcCtD
Nilotinib—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00306	0.0146	CcSEcCtD
Nilotinib—EPHB4—kidney—focal segmental glomerulosclerosis	0.00294	0.0235	CbGeAlD
Nilotinib—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.00292	0.0139	CcSEcCtD
Nilotinib—Optic neuritis—Cyclosporine—focal segmental glomerulosclerosis	0.00289	0.0138	CcSEcCtD
Nilotinib—EPHB4—cortex of kidney—focal segmental glomerulosclerosis	0.00287	0.0229	CbGeAlD
Nilotinib—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.00283	0.0135	CcSEcCtD
Nilotinib—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.00283	0.0135	CcSEcCtD
Nilotinib—TEK—kidney—focal segmental glomerulosclerosis	0.00282	0.0225	CbGeAlD
Nilotinib—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.0133	CcSEcCtD
Nilotinib—TEK—cortex of kidney—focal segmental glomerulosclerosis	0.00274	0.0219	CbGeAlD
Nilotinib—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.00271	0.0129	CcSEcCtD
Nilotinib—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.00266	0.0127	CcSEcCtD
Nilotinib—EPHB6—cortex of kidney—focal segmental glomerulosclerosis	0.00262	0.0209	CbGeAlD
Nilotinib—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.00251	0.012	CcSEcCtD
Nilotinib—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.00251	0.012	CcSEcCtD
Nilotinib—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00246	0.0118	CcSEcCtD
Nilotinib—UGT1A1—kidney—focal segmental glomerulosclerosis	0.00243	0.0194	CbGeAlD
Nilotinib—CA12—kidney—focal segmental glomerulosclerosis	0.00235	0.0188	CbGeAlD
Nilotinib—Cholestasis—Cyclosporine—focal segmental glomerulosclerosis	0.00234	0.0112	CcSEcCtD
Nilotinib—KIT—nephron tubule—focal segmental glomerulosclerosis	0.00232	0.0185	CbGeAlD
Nilotinib—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.0023	0.011	CcSEcCtD
Nilotinib—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00228	0.0109	CcSEcCtD
Nilotinib—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.0108	CcSEcCtD
Nilotinib—Hyperaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.0108	CcSEcCtD
Nilotinib—Feeling hot—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.0108	CcSEcCtD
Nilotinib—MAP2K5—cortex of kidney—focal segmental glomerulosclerosis	0.00224	0.0179	CbGeAlD
Nilotinib—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.00978	CcSEcCtD
Nilotinib—KIT—kidney—focal segmental glomerulosclerosis	0.00204	0.0163	CbGeAlD
Nilotinib—Breast pain—Cyclosporine—focal segmental glomerulosclerosis	0.00204	0.00971	CcSEcCtD
Nilotinib—ABL1—nephron tubule—focal segmental glomerulosclerosis	0.00202	0.0161	CbGeAlD
Nilotinib—PDGFRB—kidney—focal segmental glomerulosclerosis	0.00199	0.0159	CbGeAlD
Nilotinib—KIT—cortex of kidney—focal segmental glomerulosclerosis	0.00199	0.0159	CbGeAlD
Nilotinib—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00945	CcSEcCtD
Nilotinib—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.00938	CcSEcCtD
Nilotinib—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00195	0.00932	CcSEcCtD
Nilotinib—PDGFRB—cortex of kidney—focal segmental glomerulosclerosis	0.00194	0.0155	CbGeAlD
Nilotinib—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00193	0.0092	CcSEcCtD
Nilotinib—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.00914	CcSEcCtD
Nilotinib—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.00914	CcSEcCtD
Nilotinib—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.0019	0.00908	CcSEcCtD
Nilotinib—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.0089	CcSEcCtD
Nilotinib—Hearing impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.0089	CcSEcCtD
Nilotinib—CA1—kidney—focal segmental glomerulosclerosis	0.00187	0.0149	CbGeAlD
Nilotinib—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00863	CcSEcCtD
Nilotinib—ABL1—kidney—focal segmental glomerulosclerosis	0.00178	0.0142	CbGeAlD
Nilotinib—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00175	0.00833	CcSEcCtD
Nilotinib—ABL1—cortex of kidney—focal segmental glomerulosclerosis	0.00173	0.0138	CbGeAlD
Nilotinib—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.00173	0.00823	CcSEcCtD
Nilotinib—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.00818	CcSEcCtD
Nilotinib—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.00809	CcSEcCtD
Nilotinib—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.00805	CcSEcCtD
Nilotinib—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.00168	0.008	CcSEcCtD
Nilotinib—CA4—nephron tubule—focal segmental glomerulosclerosis	0.00166	0.0133	CbGeAlD
Nilotinib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00161	0.00766	CcSEcCtD
Nilotinib—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.00159	0.00758	CcSEcCtD
Nilotinib—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.00154	0.00735	CcSEcCtD
Nilotinib—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00148	0.00707	CcSEcCtD
Nilotinib—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00148	0.00704	CcSEcCtD
Nilotinib—CA4—kidney—focal segmental glomerulosclerosis	0.00146	0.0116	CbGeAlD
Nilotinib—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00145	0.00694	CcSEcCtD
Nilotinib—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00688	CcSEcCtD
Nilotinib—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00688	CcSEcCtD
Nilotinib—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00143	0.00685	CcSEcCtD
Nilotinib—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.00143	0.00681	CcSEcCtD
Nilotinib—CA4—cortex of kidney—focal segmental glomerulosclerosis	0.00142	0.0113	CbGeAlD
Nilotinib—CA2—nephron tubule—focal segmental glomerulosclerosis	0.00138	0.011	CbGeAlD
Nilotinib—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00655	CcSEcCtD
Nilotinib—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.00644	CcSEcCtD
Nilotinib—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.00633	CcSEcCtD
Nilotinib—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00132	0.0063	CcSEcCtD
Nilotinib—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00132	0.0063	CcSEcCtD
Nilotinib—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00132	0.00628	CcSEcCtD
Nilotinib—ABCG2—nephron tubule—focal segmental glomerulosclerosis	0.00127	0.0102	CbGeAlD
Nilotinib—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00606	CcSEcCtD
Nilotinib—CA2—kidney—focal segmental glomerulosclerosis	0.00121	0.00966	CbGeAlD
Nilotinib—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00576	CcSEcCtD
Nilotinib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00564	CcSEcCtD
Nilotinib—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00562	CcSEcCtD
Nilotinib—CA2—cortex of kidney—focal segmental glomerulosclerosis	0.00118	0.0094	CbGeAlD
Nilotinib—CYP2B6—nephron tubule—focal segmental glomerulosclerosis	0.00118	0.00939	CbGeAlD
Nilotinib—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.00556	CcSEcCtD
Nilotinib—CYP2C8—kidney—focal segmental glomerulosclerosis	0.00115	0.0092	CbGeAlD
Nilotinib—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00544	CcSEcCtD
Nilotinib—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00543	CcSEcCtD
Nilotinib—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00535	CcSEcCtD
Nilotinib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00521	CcSEcCtD
Nilotinib—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00511	CcSEcCtD
Nilotinib—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.0051	CcSEcCtD
Nilotinib—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.00497	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.00494	CcSEcCtD
Nilotinib—CYP2B6—kidney—focal segmental glomerulosclerosis	0.00103	0.00825	CbGeAlD
Nilotinib—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00491	CcSEcCtD
Nilotinib—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.00484	CcSEcCtD
Nilotinib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.00481	CcSEcCtD
Nilotinib—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.0048	CcSEcCtD
Nilotinib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.001	0.00477	CcSEcCtD
Nilotinib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000994	0.00474	CcSEcCtD
Nilotinib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000994	0.00474	CcSEcCtD
Nilotinib—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00098	0.00467	CcSEcCtD
Nilotinib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000977	0.00466	CcSEcCtD
Nilotinib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000974	0.00465	CcSEcCtD
Nilotinib—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000974	0.00465	CcSEcCtD
Nilotinib—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000969	0.00462	CcSEcCtD
Nilotinib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000969	0.00462	CcSEcCtD
Nilotinib—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000966	0.00461	CcSEcCtD
Nilotinib—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000966	0.00461	CcSEcCtD
Nilotinib—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.000947	0.00452	CcSEcCtD
Nilotinib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00094	0.00448	CcSEcCtD
Nilotinib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000937	0.00447	CcSEcCtD
Nilotinib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000897	0.00428	CcSEcCtD
Nilotinib—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000894	0.00427	CcSEcCtD
Nilotinib—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000892	0.00426	CcSEcCtD
Nilotinib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000892	0.00426	CcSEcCtD
Nilotinib—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000888	0.00423	CcSEcCtD
Nilotinib—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000885	0.00422	CcSEcCtD
Nilotinib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000881	0.0042	CcSEcCtD
Nilotinib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000877	0.00418	CcSEcCtD
Nilotinib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000874	0.00417	CcSEcCtD
Nilotinib—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00086	0.0041	CcSEcCtD
Nilotinib—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000832	0.00397	CcSEcCtD
Nilotinib—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000828	0.00395	CcSEcCtD
Nilotinib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000809	0.00386	CcSEcCtD
Nilotinib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000804	0.00384	CcSEcCtD
Nilotinib—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.0008	0.00382	CcSEcCtD
Nilotinib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000797	0.0038	CcSEcCtD
Nilotinib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000788	0.00376	CcSEcCtD
Nilotinib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000782	0.00373	CcSEcCtD
Nilotinib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.00078	0.00623	CbGeAlD
Nilotinib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000777	0.00371	CcSEcCtD
Nilotinib—CYP2D6—kidney—focal segmental glomerulosclerosis	0.000768	0.00613	CbGeAlD
Nilotinib—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000765	0.00365	CcSEcCtD
Nilotinib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00076	0.00363	CcSEcCtD
Nilotinib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000747	0.00356	CcSEcCtD
Nilotinib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000732	0.00349	CcSEcCtD
Nilotinib—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000728	0.00347	CcSEcCtD
Nilotinib—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000721	0.00344	CcSEcCtD
Nilotinib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000718	0.00342	CcSEcCtD
Nilotinib—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.0007	0.00334	CcSEcCtD
Nilotinib—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000698	0.00333	CcSEcCtD
Nilotinib—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000695	0.00332	CcSEcCtD
Nilotinib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000678	0.00323	CcSEcCtD
Nilotinib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00067	0.0032	CcSEcCtD
Nilotinib—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000661	0.00315	CcSEcCtD
Nilotinib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000661	0.00315	CcSEcCtD
Nilotinib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000661	0.00315	CcSEcCtD
Nilotinib—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000659	0.00314	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000657	0.00313	CcSEcCtD
Nilotinib—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000653	0.00312	CcSEcCtD
Nilotinib—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000647	0.00308	CcSEcCtD
Nilotinib—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000639	0.00305	CcSEcCtD
Nilotinib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000634	0.00302	CcSEcCtD
Nilotinib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00063	0.003	CcSEcCtD
Nilotinib—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000628	0.00502	CbGeAlD
Nilotinib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000622	0.00297	CcSEcCtD
Nilotinib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000621	0.00296	CcSEcCtD
Nilotinib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000616	0.00294	CcSEcCtD
Nilotinib—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000613	0.00292	CcSEcCtD
Nilotinib—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000604	0.00288	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000577	0.00275	CcSEcCtD
Nilotinib—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000573	0.00273	CcSEcCtD
Nilotinib—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000569	0.00272	CcSEcCtD
Nilotinib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000565	0.0027	CcSEcCtD
Nilotinib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000558	0.00266	CcSEcCtD
Nilotinib—ABCB1—kidney—focal segmental glomerulosclerosis	0.000552	0.00441	CbGeAlD
Nilotinib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000551	0.00263	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000547	0.00261	CcSEcCtD
Nilotinib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000546	0.00261	CcSEcCtD
Nilotinib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000542	0.00259	CcSEcCtD
Nilotinib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000542	0.00259	CcSEcCtD
Nilotinib—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000538	0.00429	CbGeAlD
Nilotinib—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000522	0.00249	CcSEcCtD
Nilotinib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000518	0.00247	CcSEcCtD
Nilotinib—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000503	0.0024	CcSEcCtD
Nilotinib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000501	0.00239	CcSEcCtD
Nilotinib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000501	0.00239	CcSEcCtD
Nilotinib—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000467	0.00223	CcSEcCtD
Nilotinib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000455	0.00217	CcSEcCtD
Nilotinib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000448	0.00214	CcSEcCtD
Nilotinib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000434	0.00207	CcSEcCtD
Nilotinib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000419	0.002	CcSEcCtD
Nilotinib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000403	0.00192	CcSEcCtD
Nilotinib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.0004	0.00191	CcSEcCtD
Nilotinib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000399	0.0019	CcSEcCtD
Nilotinib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000397	0.00189	CcSEcCtD
Nilotinib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000376	0.0018	CcSEcCtD
Nilotinib—Imatinib—ALB—focal segmental glomerulosclerosis	0.000202	1	CrCbGaD
Nilotinib—BRAF—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.55e-05	0.000101	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.53e-05	0.000101	CbGpPWpGaD
Nilotinib—CA7—Metabolism—ALB—focal segmental glomerulosclerosis	3.51e-05	0.0001	CbGpPWpGaD
Nilotinib—HCK—Disease—NOS2—focal segmental glomerulosclerosis	3.49e-05	9.95e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.48e-05	9.94e-05	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—TGFB1—focal segmental glomerulosclerosis	3.46e-05	9.87e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.44e-05	9.83e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP2—focal segmental glomerulosclerosis	3.42e-05	9.77e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—MMP9—focal segmental glomerulosclerosis	3.42e-05	9.76e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP2—focal segmental glomerulosclerosis	3.41e-05	9.73e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AGT—focal segmental glomerulosclerosis	3.38e-05	9.65e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD79A—focal segmental glomerulosclerosis	3.35e-05	9.57e-05	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	3.31e-05	9.45e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	3.3e-05	9.41e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—ALB—focal segmental glomerulosclerosis	3.29e-05	9.39e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD79A—focal segmental glomerulosclerosis	3.28e-05	9.37e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	3.28e-05	9.36e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—ALB—focal segmental glomerulosclerosis	3.27e-05	9.35e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.27e-05	9.34e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD79A—focal segmental glomerulosclerosis	3.27e-05	9.33e-05	CbGpPWpGaD
Nilotinib—CA12—Metabolism—ALB—focal segmental glomerulosclerosis	3.25e-05	9.28e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—FN1—focal segmental glomerulosclerosis	3.25e-05	9.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP2—focal segmental glomerulosclerosis	3.25e-05	9.27e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	3.24e-05	9.26e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AGT—focal segmental glomerulosclerosis	3.24e-05	9.25e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.24e-05	9.24e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.22e-05	9.18e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—NOS2—focal segmental glomerulosclerosis	3.21e-05	9.16e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD40LG—focal segmental glomerulosclerosis	3.21e-05	9.15e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—LPL—focal segmental glomerulosclerosis	3.19e-05	9.11e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—LPL—focal segmental glomerulosclerosis	3.19e-05	9.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	3.12e-05	8.92e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—ALB—focal segmental glomerulosclerosis	3.12e-05	8.9e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—LIPC—focal segmental glomerulosclerosis	3.12e-05	8.89e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD79A—focal segmental glomerulosclerosis	3.11e-05	8.89e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AGT—focal segmental glomerulosclerosis	3.11e-05	8.87e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.06e-05	8.74e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.04e-05	8.69e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD40LG—focal segmental glomerulosclerosis	3.03e-05	8.66e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.01e-05	8.59e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3e-05	8.56e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3e-05	8.56e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.97e-05	8.48e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.96e-05	8.45e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—SERPINE1—focal segmental glomerulosclerosis	2.94e-05	8.38e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.92e-05	8.33e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—LPL—focal segmental glomerulosclerosis	2.91e-05	8.29e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.83e-05	8.08e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.82e-05	8.04e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.78e-05	7.92e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.76e-05	7.88e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—LPL—focal segmental glomerulosclerosis	2.75e-05	7.85e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.74e-05	7.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.74e-05	7.83e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.74e-05	7.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD40LG—focal segmental glomerulosclerosis	2.73e-05	7.8e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AGT—focal segmental glomerulosclerosis	2.73e-05	7.8e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.72e-05	7.76e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.7e-05	7.72e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	2.7e-05	7.71e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.7e-05	7.71e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—ALB—focal segmental glomerulosclerosis	2.7e-05	7.7e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.69e-05	7.69e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD79A—focal segmental glomerulosclerosis	2.69e-05	7.68e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.69e-05	7.67e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.68e-05	7.66e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD40LG—focal segmental glomerulosclerosis	2.68e-05	7.64e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD40LG—focal segmental glomerulosclerosis	2.66e-05	7.61e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	2.64e-05	7.55e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.64e-05	7.53e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—ALB—focal segmental glomerulosclerosis	2.59e-05	7.4e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.57e-05	7.35e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.56e-05	7.31e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.56e-05	7.31e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.56e-05	7.31e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.55e-05	7.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.55e-05	7.27e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD40LG—focal segmental glomerulosclerosis	2.54e-05	7.24e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.53e-05	7.21e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—NOS2—focal segmental glomerulosclerosis	2.49e-05	7.12e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—ALB—focal segmental glomerulosclerosis	2.49e-05	7.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—LPL—focal segmental glomerulosclerosis	2.48e-05	7.07e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.47e-05	7.06e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.44e-05	6.96e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.42e-05	6.92e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—ALB—focal segmental glomerulosclerosis	2.38e-05	6.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.34e-05	6.68e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	2.33e-05	6.64e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.33e-05	6.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.31e-05	6.58e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.3e-05	6.58e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.3e-05	6.58e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	2.28e-05	6.52e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NOS2—focal segmental glomerulosclerosis	2.27e-05	6.48e-05	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.26e-05	6.45e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.26e-05	6.45e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.26e-05	6.44e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.25e-05	6.42e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.24e-05	6.39e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.24e-05	6.38e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.21e-05	6.32e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.2e-05	6.28e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD40LG—focal segmental glomerulosclerosis	2.19e-05	6.26e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NOS2—focal segmental glomerulosclerosis	2.15e-05	6.13e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.14e-05	6.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.14e-05	6.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.14e-05	6.1e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.13e-05	6.08e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.12e-05	6.05e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.12e-05	6.04e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.11e-05	6.03e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.11e-05	6.02e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—SERPINE1—focal segmental glomerulosclerosis	2.1e-05	5.99e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.1e-05	5.99e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—ALB—focal segmental glomerulosclerosis	2.1e-05	5.98e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.08e-05	5.94e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.07e-05	5.91e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.07e-05	5.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.03e-05	5.81e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.01e-05	5.74e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—LPL—focal segmental glomerulosclerosis	1.99e-05	5.68e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.98e-05	5.67e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.97e-05	5.63e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.96e-05	5.59e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	1.95e-05	5.56e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—LIPC—focal segmental glomerulosclerosis	1.94e-05	5.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS2—focal segmental glomerulosclerosis	1.94e-05	5.52e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.93e-05	5.51e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.93e-05	5.5e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.93e-05	5.5e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.92e-05	5.49e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.91e-05	5.46e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—SERPINE1—focal segmental glomerulosclerosis	1.91e-05	5.46e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—LPL—focal segmental glomerulosclerosis	1.9e-05	5.43e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.86e-05	5.32e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—TGFB1—focal segmental glomerulosclerosis	1.85e-05	5.29e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.85e-05	5.28e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.83e-05	5.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.82e-05	5.21e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—SERPINE1—focal segmental glomerulosclerosis	1.81e-05	5.16e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.79e-05	5.1e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.78e-05	5.09e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.77e-05	5.06e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.77e-05	5.04e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.75e-05	5e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.74e-05	4.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.74e-05	4.95e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CTGF—focal segmental glomerulosclerosis	1.71e-05	4.87e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.71e-05	4.87e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.7e-05	4.85e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.69e-05	4.83e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.66e-05	4.74e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.65e-05	4.7e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.64e-05	4.69e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	1.64e-05	4.68e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SERPINE1—focal segmental glomerulosclerosis	1.63e-05	4.65e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	1.63e-05	4.65e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AGT—focal segmental glomerulosclerosis	1.63e-05	4.64e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	1.61e-05	4.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.61e-05	4.6e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.61e-05	4.59e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.61e-05	4.59e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.57e-05	4.49e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.57e-05	4.47e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS2—focal segmental glomerulosclerosis	1.55e-05	4.43e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.53e-05	4.35e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.52e-05	4.35e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.48e-05	4.24e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.48e-05	4.24e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.48e-05	4.21e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.47e-05	4.2e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.45e-05	4.15e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	1.44e-05	4.12e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.44e-05	4.1e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.43e-05	4.08e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.43e-05	4.07e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.39e-05	3.97e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	1.38e-05	3.94e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.38e-05	3.93e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.37e-05	3.92e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.36e-05	3.87e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	1.35e-05	3.84e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.34e-05	3.83e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.34e-05	3.82e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	1.34e-05	3.81e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.33e-05	3.8e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—focal segmental glomerulosclerosis	1.33e-05	3.78e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.32e-05	3.76e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—SERPINE1—focal segmental glomerulosclerosis	1.31e-05	3.73e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.27e-05	3.63e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.27e-05	3.62e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.26e-05	3.59e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—focal segmental glomerulosclerosis	1.25e-05	3.56e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.22e-05	3.49e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—focal segmental glomerulosclerosis	1.21e-05	3.44e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.2e-05	3.43e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.19e-05	3.4e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	1.19e-05	3.38e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—LPL—focal segmental glomerulosclerosis	1.18e-05	3.38e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.18e-05	3.36e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	1.18e-05	3.36e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.16e-05	3.31e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—focal segmental glomerulosclerosis	1.14e-05	3.26e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.14e-05	3.26e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.14e-05	3.25e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.13e-05	3.21e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.12e-05	3.19e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.12e-05	3.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.1e-05	3.14e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.09e-05	3.12e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.08e-05	3.09e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.06e-05	3.02e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	1.06e-05	3.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—focal segmental glomerulosclerosis	1.03e-05	2.94e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.03e-05	2.93e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AGT—focal segmental glomerulosclerosis	1.01e-05	2.89e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	1e-05	2.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.7e-06	2.77e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.37e-06	2.67e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.28e-06	2.65e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.16e-06	2.61e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	8.81e-06	2.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.74e-06	2.5e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	8.72e-06	2.49e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	8.56e-06	2.44e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.56e-06	2.44e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.45e-06	2.41e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—focal segmental glomerulosclerosis	8.26e-06	2.36e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	8.22e-06	2.35e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	8.15e-06	2.33e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.11e-06	2.32e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8e-06	2.28e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—focal segmental glomerulosclerosis	7.76e-06	2.22e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	7.75e-06	2.21e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	7.46e-06	2.13e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.2e-06	2.06e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.14e-06	2.04e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.05e-06	2.01e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	7.03e-06	2.01e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.02e-06	2e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	6.97e-06	1.99e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.69e-06	1.91e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	6.57e-06	1.88e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.78e-06	1.65e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	5.73e-06	1.63e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	5.4e-06	1.54e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	5.37e-06	1.53e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	5.35e-06	1.53e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	4.6e-06	1.31e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	3.53e-06	1.01e-05	CbGpPWpGaD
